logo-loader

Hutchison China MediTech kicks off first human trial for potential new cancer drug

Published: 03:34 14 Feb 2017 EST

rsz_shutterstock_161304095
The drug under trial takes a completely new approach to tackling cancer

Hutchison China MediTech Limited (LON:HCM, NASDAQ:HCM) has launched a phase I clinical trial in Australia of a drug that takes a completely new approach to tackling cancer.

HMPL-453 targets fibroblast growth factor receptors. These are central to several biological processes including the formation of blood vessels that supply tumours (a process called  angiogenesis) as well as tissue growth and repair.

It is also thought the new drug, which is a small molecule, chemical entity rather than a harder-to-develop biologic, could prevent drug resistance.

It is a “sub-family” of the new breed of tyrosine kinases, which potentially provide an ‘on-off switch’ for cancer.

Chi-Med will look at the safety and how well tolerated the drug is while escalating the dosage.

HMPL-453 is being administered to cancer patients where treatment options have run out, so researchers will look for signs of efficacy too.

In pre-clinical studies, it was more potent and selective in the pathways targeted than other drugs in its class. It also had a favourable safety profile.

Rush Rare Metals Advances Two Key Projects: Uranium in Wyoming and Niobium...

Rush Rare Metals CEO Peter Smith joined Steve Darling from Proactive to share news about the mineral exploration company's focus on its Boxi Property in Quebec and the Copper Mountain Project in Wyoming. The company recently announced the staking of the Knob claims in Wyoming, comprising 52...

9 minutes ago